Aceragen Inc

Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm’s product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Exton, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aceragen, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the research and development of medications for rare and orphan diseases. The firm's product portfolio includes ACG-801 and ACG-701, which targets Farber Disease, Melioidosis, and Cystic Fibrosis. The company was founded in 1989 and is headquartered in Durham, NC.

DURHAM, N.C. and EXTON, Pa., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Capital Market (“Nasdaq”) by filing a Form 25 with the Securities and Exchange Commission (the “SEC”) on or about August 15, 2023. As previously disclosed, on August 14, 2023, the Company expects to hold a special meeting seeking stockholder approval to effect a transfer and assignment of substantially all of the Company's assets to an assignee for the benefit of creditors (the “Assignment Proposal”). Subject to stockholder approval of the Assignment Proposal, and in order to ensure an orderly delisting process, the Company has determined to voluntarily terminate the listing of its common stock on the Nasdaq by filing a Form 25 with the SEC on or about August 15, 2023.

Aceragen, Inc. to Delist from The Nasdaq Stock Market

DURHAM, N.C. and EXTON, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (the “Company”) (Nasdaq: ACGN), announced today that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q's original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance.

Aceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

DURHAM, N.C. and EXTON, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aceragen, Inc. (Nasdaq: ACGN) a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification.

Aceragen Announces Recommendation of Data Monitoring Committee in Terra Study

News for Aceragen Inc Stock (ACGN)